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Abstract: 
Purpose: The development of Clostridium difficile infection after cystectomy is associated with 
significant morbidity and mortality. We implemented a prospective screening program to 
identify asymptomatic carriers of Clostridium difficile and assessed its impact on clinical 
Clostridium difficile infection rates compared to historical matched controls. 
Materials and Methods: Prospective Clostridium Difficile screening prior to cystectomy began 
in March 2015.  The 380 consecutive patients undergoing cystectomy prior to initiation of 
screening (control cohort) were matched based on 5 clinical factors with the 386 patients who 
underwent cystectomy from March 2015 to December 2017 (trial cohort).  Screened positive 
patients were placed in contact isolation and treated prophylactically with Metronidazole.  
Multivariable models were built on an intention-to-screen and an effectiveness of screening basis 
to determine if screening reduced the rates of symptomatic Clostridium Difficile infections 
postoperatively.  
Results: With the implementation of the screening protocol, Clostridium difficile infections rates 
declined from 9.4 to 5.5% (OR 0.52, p=0.0268) on an intention-to-screen protocol and from 9.2 
to 4.9% on an effectiveness of screening protocol (OR 0.46, p=0.0174).  
Conclusions: Clostridium difficile screening prior to cystectomy is associated with a significant 
decrease in rates of clinically symptomatic infections postoperatively.  These results should be 
confirmed in a randomized controlled trial. 
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Introduction: 
 Clostridium difficile infectious colitis (CDI) prolongs hospital stays and increases 
complication rates, hospital costs and mortality worldwide 1-6.  Unfortunately, the incidence of 
CDI has increased 5,7,8.  A new strain of Clostridium difficile (CD) was discovered in North 
America in 2005 which exhibited greater toxicity and was associated with poor outcomes 4,9.   
Twelve and a half percent of these infected patients experienced a severe outcome defined as an 
ICU admission, colectomy, or death with older patients more likely to experience a severe 
outcome. Mortality with these toxic strains range from 5.4% for patients age 61-70 and rises with 
each decade of life to 14.7% for patients age >90 9.  Recent studies also suggest that 
asymptomatic carriers of CD can transmit to others and therefore contribute to increased rates of 
CDI in a hospital setting particularly when patient rooms are not easily isolated 10-15. 
 Cystectomy patients are at higher risk of CDI than the general patient population due to 
their increased age, underlying comorbidities, and recent antibiotic exposure with published rates 
of CDI in cystectomy patients ranging from 1.4-14% 16-21.  It has been demonstrated that the 
development of CDI after cystectomy is associated with a 2.5-fold increase in mortality and adds 
approximately $22,634 in cost per hospitalization per patient 17.  Our institution’s CDI incidence 
from 2010 to 2013 was closer to the high end of this range as reported in 2015 19.  The incidence 
of asymptomatic CD carriage is unfortunately unknown in cystectomy patients. 
Screening of asymptomatic patients for CD is discouraged by the Infectious Disease 
Society of America (IDSA) and the Center for Disease Control (CDC), but recent studies suggest 
a benefit in high-risk populations 22-25.  We implemented a prospective screening program prior 
to cystectomy to address our high incidence of CDI despite the adoption of the IDSA and CDC 
recommendations for the isolation and management of symptomatic CDI patients.  We 
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hypothesized that preoperative screening in cystectomy patients would decrease our institutions 
incidence of CDI by allowing us to isolate and treat CD carriers prior to transmission or 
development of CDI. 
Methods: 
Study Cohorts: 
A total of 765 consecutive patients underwent cystectomy (simple or radical) at our 
institution between June 2012 and December 2017.  This sample included a cohort of 379 
patients who underwent cystectomy between June 2012 – February 2015 prior to the initiation of 
the screening trial (control cohort) and 386 patients who underwent cystectomy March 2015 – 
December 2017 after the initiation of the prospective screening for CD trial (trial cohort).  The 
trial and control cohorts were then matched based on five demographical and clinical factors: age 
within 5 years, cancer, preoperative antacid use (use of a proton pump inhibitor or a histamine2 
channel antagonist), prolonged antibiotic use (>24 hours perioperative), and receipt of 
neoadjuvant chemotherapy.  Each patient in the trial cohort had at least one matched patient in 
the control cohort based on the matching criteria, and vice versa for each patient in the control 
cohort. 
The matched sample consisted of 720 patients, including 358 patients in the trial cohort 
and 362 patients in the control cohort.  Among the patients in the trial cohort, 283 patients had 
screening results for D (trial screened) and 75 patients had insufficient screening results (trial 
unscreened) for CD due to lab errors or refusal.  
We defined the intention-to-screen cohort as patients within the trial (n=358) and patients 
in the control cohort (n=362).  The effectiveness of screening cohort was defined as patients 
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within the trial who were screened (n=258) and patients who were unscreened (n=437, including 
362 controls and 75 trial patients without screening results).   All our subsequent analysis were 
based on those two cohorts.  
Screening: 
Preoperative screening for CD in cystectomy patients began in March of 2015.  Screening 
consisted of rectal examination immediately prior to cystectomy while under general anesthesia.   
Stool samples were collected and sent to the lab where a CD PCR assay was run.  Our laboratory 
PCR assay tests for the gene responsible for toxin B of CD.  If stool was not obtained during the 
digital rectal examination, a swab of rectal mucous was used for analysis.  Carriers of CD 
(screened positive individuals) were placed into isolation rooms with appropriate contact 
precautions.   Carriers were also treated with intravenous metronidazole (500mg three times 
daily) until the return of bowel function.  Return of bowel function was defined as passage of 
flatus.  Carrier negative patients were otherwise treated on a standardized clinical pathway that 
has been in existence since 2012 with little change (Figure 1).   
Primary Outcomes: 
The primary outcome was the incidence of post-operative CDI defined as 3 or more 
diarrhea episodes per day associated with a positive CD assay within 30 days of the operation.  
Patients’ demographical and clinical factors were collected prospectively on all patients as part 
of quality improvement measures into an IRB approved departmental database.   
Statistical Analysis: 
Patients’ demographic and clinical characteristics were reported and compared between 
the screened trial cohort (n=283), the unscreened trial cohort (n=75) and the control cohort 
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(n=362).  Analysis of Variance (ANOVA) and the Kruskal-Wallis Test were used to compare 
normally and non-normally distributed continuous variables, respectively.  Categorical variables 
were compared using the Chi-Square Test.  Logistic regression models were fit to examine the 
cohort difference in post-surgery CDI using the intention-to-screen and the effectiveness of 
screening cohorts.  All models included known risk factors for CDI, i.e., age, cancer, antibiotic 
use, antacid use, and chemotherapy as covariates.  All analysis was completed at a two-tailed 
significance level of 0.05 using SAS 9.4 (SAS Institute, Cary, NC). 
Results: 
Baseline Demographics and Clinical Characteristics: 
A flowchart is presented in Figure 2 that defines the patient population as well as the rate 
of CDI in each cohort.  Patient demographic and clinical characteristics by cohort are 
summarized in Table 1.  Overall, the groups were well matched.  There was a significant 
difference in antacid use prior to cystectomy between cohorts. Compared with the control cohort, 
patients in the trial cohort were more likely to be taking antacids prior to cystectomy (30.1% vs 
19.1%, p=<0.0001).  The method of urinary reconstruction was different between the three 
groups (p=0.0026)  The trial unscreened population was more likely to receive a non-continent 
diversion than the other cohorts (63.6% trial screened vs 74.7% trial unscreened vs 63.4% 
control). 
Intention-to-Screen Analysis of CDI: 
The rate of post-operative CDI was 9.4% for the control cohort and 5.5% for the trial 
cohort.  Absolute risk reduction was 3.9% with a number needed to screen of 26 patients to 
prevent one postoperative CDI. After adjusting for patient’s age, cancer status, use of prolonged 
antibiotics, use of antacid, and status of receiving neoadjuvant chemotherapy, the intention-to-
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screen led to a 48% reduction in the odds of CDI (OR 0.52, 95%CI 0.29-0.93, p=0.0268) (Table 
2).    
Effect of Screening Analysis of CDI: 
About 21% of patients in the trial cohort did not have screening results (trial unscreened) 
due to the inadequate laboratory stool specimen. The rate of CDI was similar in the control 
cohort and the trial unscreened cohort (9.4 vs 8.0%, p=0.7870). The rate of CDI was 4.9% in the 
trial screened cohort and 9.2% in the unscreened cohort (the control cohort and the trial 
unscreened cohort combined). Absolute risk reduction was 4.3% with a number needed to screen 
of 24 patients to prevent one postoperative CDI.  After adjusting for patient’s age, cancer status, 
use of prolonged antibiotics, use of antacid, and status of receiving neoadjuvant chemotherapy, 
the protective effect of screening demonstrated a 54% reduction in the odds (OR 0.46, 95%CI 
0.24-0.87, p=0.0174) on post-operative CDI (Table 3). 
Adverse events: 
No adverse events were identified from screening or treating screened positive patients 
with a short course of antibiotics.  No patients experienced an acute reaction or allergy to 
metronidazole. Specifically, only 1 patient had an ileus and 1 patient required readmission who 
received metronidazole.   
Postoperative complications did not differ between groups as shown in Table 1.  
However, three unscreened patients died who were diagnosed with CDI postoperatively (2 
control, 1 trial unscreened).  No patients diagnosed with CDI in the trial cohort died 
postoperatively.  Two of the deaths in the control cohort were clearly attributable to CDI. 
Discussion: 
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After screening for CD was implemented, our institution’s incidence of CDI decreased 
substantially in patients undergoing cystectomy.  When controlling for demographical and 
clinical factors, screening as well as the “intention to screen” had a protective effect on 
developing CDI.  None of the other clinical covariates were predictors of developing CDI.  Fifty-
two (18.4%) patients screened positive for CD (asymptomatic carriers).  Screened positive 
patients received a short course of metronidazole post-operatively (mean length of 3 days).  The 
overall use of antibiotics was low given the short duration of use and the low percentage of 
asymptomatic carriers.  The incidence of CDI at our institution prior to implementation of the 
screening trial was 9.4%.  Thus, we would have anticipated that 34 patients would have 
developed CDI during the subsequent two years if screening had not been initiated.  Instead, only 
20 patients developed CDI.  We treated 52 patients with a short course of metronidazole in order 
to prevent the treatment of 14 patients with a protracted course of metronidazole and/or 
vancomycin and the associated potential morbidity and mortality of post-operative CDI.   The 
limitation of morbidity and mortality secondary to post-operative CDI must be stressed.  Three 
of the fifty-four patients who developed CDI died postoperatively with two of these events 
clearly attributable to CDI.  All deaths occurred in unscreened patients.  
We hypothesized that the lower incidence of CDI in the trial cohort is due to two main 
interventions.  First, asymptomatic carriers of CD were placed in single-occupancy rooms under 
contact isolation with stricter hand washing policies.  The separation of carriers likely reduced 
the transmission of CD from carrier to non-carriers.  This hypothesis is supported by the 4.6% 
reduction in CDI incidence between the control cohort and the trial cohort members who 
screened negative.   Results of recent studies support our hypothesis.  Genome sequencing was 
performed in 1,223 patients diagnosed with CDI in the United Kingdom.   Forty-five percent of 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
cases had significant genetic diversity to indicate that the infection originated from another 
source other than symptomatic cases 26.  Authors concluded that transmission likely occurred 
from asymptomatic carriers of CD.  Another group evaluated 3,006 patients were screened for 
CD over a 5-month period.  Molecular subtyping determined that 29% of active CDI cases were 
genetically associated with asymptomatic carriers in the same hospital 11.  A smaller study of 634 
patients reported that 84% of nosocomial CDI were preceded by documented admission of the 
strain to the ward by an asymptomatic carrier 16.    Plausible mechanisms of transmission include 
contamination of the environment and caregivers’ hands 13,27.  These studies support the 
hypothesis that asymptomatic carriers of CD can transmit CD to others and contribute to 
increased CDI rates in hospitals.  Our data suggests that isolation of asymptomatic carriers of CD 
may decrease symptomatic CDI within hospital units presumably by reduced transmission.  
Second, precautionary treatment with metronidazole likely reduced the rates of 
symptomatic infection in carriers of CD.  Colonization with CD was found to be an independent 
risk factor for developing symptomatic infections in patients admitted to the Intensive Care Unit 
25
.  By prophylactically treating colonized patients, we demonstrated a 3.6% reduction in CDI 
incidence between the control cohort and the trial cohort members who screened positive.  
Antibiotic administration in carriers of CD is controversial and not supported by the American 
College of Gastroenterology (ACG).  This recommendation is based off of an older study which 
focused on eliminating asymptomatic carriage of CD 28.  This was not our intent as we sought to 
reduce symptomatic CDI in a high-risk cohort.  A recent quasi-experimental study evaluated the 
role of isolation without prophylactic antibiotic treatment of asymptomatic carriers on incidence 
of CDI.  Carriers of CD in this trial were placed in contact isolation precautions until discharge.  
Compared to the pre-intervention control period, the incidence of CDI was drastically reduced 
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after screening (3.9 per 10,000 patient days versus 6.0 per 10,000 patient days). This group 
concluded that screening and isolating carriers of CD was associated with lower rates of hospital 
acquired CDI 24.  Our results would appear to corroborate these findings.  Future studies will 
need to assess the impact of isolation and prophylactic treatment to determine the optimal 
intervention strategy. 
The results of our study should be considered in the context of several limitations.  First, 
our trial represents an observational quality improvement project where rates of CDI in a 
screened population were compared with a control population.   Further multi-institutional and 
randomized investigations are needed to confirm our findings.  However, our results give 
sufficient proof of concept to justify the design and conduction of these more laborious and 
costly evaluations.  We fully acknowledge that we are presenting an observation of a clinical 
change in practice at our institution.  The quasi-experimental pre-post design is limited in the 
ability to assess changes in CDI rates over time that may have been due to global institutional 
interventions.  However, no other obvious changes in practice aside from the screening protocol 
explain the lower rates of CDI.  All patients were treated by the same urologists and admitted to 
the same floor of the hospital throughout the period of analysis.  To support this, the rate of CDI 
during the study period on the urology ward declined by 38% when compared to the control 
period which exceeded the CDI rate reduction of the entire hospital (32%).  CDI rates on other 
floors, including medical and colorectal surgical wards, demonstrated a less pronounced rate of 
CDI reduction ranging from 5 to 33%.  The generalizability of our results may be limited due to 
the higher incidence rate of CDI compared to other institutions 16-19.  However, CDI rates are 
rising and recent reports suggest that CDI rates in cystectomy patients may be even higher at 
other institutions 5,20.   Moreover, multiple agencies (ACG, IDSA, CDC) have produced 
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guidelines against screening for CD in the general population 22,23.  Our results directly 
contradict these statements and suggest that screening in high-risk patients requires further 
attention.  Lastly, recent reports suggest that isolation of asymptomatic carriers alone 
substantially lowers CDI rates 24.  Further evaluation on the necessity of prophylactic antibiotic 
administration and isolation versus isolation only of asymptomatic carriers is needed.   
These limitations notwithstanding, we believe that our data is compelling enough to 
warrant future formal study of this subject.  To our knowledge, this is the first report 
investigating the role of screening for CD in patients undergoing cystectomy.  This patient 
population is at high-risk for CDI due to a multitude of patient and disease-related risk factors.   , 
Screening reduced the risk of CDI by 46-54%.  Our prospective, low-risk screening program 
demonstrated significant promise in reducing morbidity and mortality secondary to CDI in 
patients undergoing cystectomy. 
Conclusion: 
Implementing a screening protocol in cystectomy patients was associated with 
significantly decreased incidence of CDI. Although this data is observational, we believe it is 
compelling. Further study in the form of randomized trials is warranted to confirm our findings. 
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Table 1: Patient Demographics and Clinical Characteristics by Cohort 
 
 Control Cohort 
(n=362) 
Trial Unscreened 
Cohort (n=75) 
Trial Screened 
Cohort 
(n=283) 
p value 
Age (IQR) 67 (60-76) 69 (58-75) 67 (57-75) 0.45221 
Gender, male (%) 266 (73.5) 56 (74.7) 210 (74.2) 0.96592 
Pre-op Antacid Use, 
yes (%) 
69 (19.1) 20 (26.7) 88 (31.1) 0.00182 
Pre-op Chemotherapy, 
yes (%) 
98 (27.1) 17 (22.7) 95 (33.6) 0.08392 
Prolonged Antibiotics 
(%) 
95 (26.2) 26 (34.7) 72 (25.4) 0.26072 
Cancer, yes (%) 302 (83.4) 59 (78.7) 249 (88) 0.08532 
Diversion Type (%) 
   Ileal Conduit 
   Indiana Pouch 
   Neobladder 
   Other 
 
229 (63.4) 
82 (22.7) 
50 (13.9) 
0 
 
56 (77.7) 
10 (13.3) 
8 (10.7) 
1 (1.3) 
 
180 (63.6) 
48 (17) 
54 (19.1) 
1 (0.4) 
0.00262 
CDI* 34 (9.4) 6 (8) 14 (4.9) 0.10262 
C. diff Carrier Status 
(%) 
   Positive 
   Negative 
   Unknown 
 
 
0 
0 
362 (100) 
 
 
0 
0 
75 (100) 
 
 
52 (18.4) 
231 (81.6) 
0 (0) 
-- 
Hospital Days (IQR) 8 (6-10) 7 (6-12) 7 (6-10) 0.12633 
Clavien (IQR) 1 (0-2) 1 (0-2) 0 (0-2) 0.09493 
* Clostridium Difficile Infection  
1 ANOVA 
2Chi-Square 
3Kruskal-Wallis 
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Table 2: Logistic Regression Model: Effect of Trial on CDI 
Effect (ref) Odds Ratio 95% CI p value 
Age 1.02 1.00-1.05 0.0855 
Cancer (no) 1.37 0.48-3.92 0.5558 
Prolonged antibiotics (no) 1.15 0.61-2.17 0.6627 
Antacid use (no) 1.64 0.88-3.05 0.1224 
Neoadjuvant chemotherapy (no) 1.42 0.75-2.69 0.2763 
Intention to Screen (Control) 0.52 0.29-0.93 0.0268 
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Table 3: Logistic Regression Model: Effect of Screening on CDI 
Effect (ref) Odds Ratio 95% CI p value 
Age 1.02 1.00-1.05 0.0874 
Cancer (no) 1.41 0.49-4.04 0.5188 
Prolonged antibiotics (no) 1.14 0.60-2.15 0.6862 
Antacid use (no) 1.65 0.88-3.07 0.1169 
Neoadjuvant chemotherapy (no) 1.45 0.77-2.75 0.2523 
Intention to Screen (Control + 
Trial Unscreened) 
0.46 0.24-0.87 0.0174 
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Figure 1: Perioperative Cystectomy Pathway at Indiana University 
 
 
Preoperative
•Preadmission counseling
•Limited antibiotic prophylaxis (24 
hours of coverage)
•Cefoxitin is institutional 
preference unless contraindicated
•Thromboprophylaxis
•No bowel preparation
•Nutritional Supplementation
Intraoperative
•Mid-thoracic epidural 
anesthesia/analgesia
•Short-acting anesthetic agents
•Avoidance of salt and fluid overload
Postoperative
•No nasogastric tubes
•Early oral nutrition
•Solid foods by day 3-4
•Early mobilization
•Physical therapy consultation
•Stimulation of gut motility
•Regular use of Alvimopan
•Multi-modal pain control
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Figure 2:  Flow Chart of the Study Population 
 
 
 
 
Total Cohort
n=765
CDI Rate (61, 8.0%)
Matched Cohort
n=720
CDI Rate (54, 7.5%)
Control Cohort
n=362
CDI Rate (34, 9.4%)
Trial Cohort
n=358
CDI Rate (20, 5.5%)
Trial Screened
n=283
CDI Rate (14, 4.9%)
Screened Positive
n= 52
CDI Rate (3, 5.8%)
Screened Negative
n= 231
CDI Rate (11, 4.9%)
Trial Unscreened
n= 75
CDI Rate (6, 8%)
